Systemic sclerosis & Raynaud's
Predictors of rituximab efficacy in systemic sclerosis-associated interstitial lung disease: machine-learning analysis of the DESIRES trial
Authors' conclusion
Even slight elevations in serum CRP levels are associated with the improvement in ppFVC and may serve as predictors of rituximab efficacy in SSc-ILD.
Study context
- Population
- Patients with SSc-ILD in the DESIRES trial
- Participants
- 48 patients
- Comparison
- Rituximab vs placebo, by baseline-defined subpopulations
- Primary endpoint
- Efficacy of rituximab on percentage of predicted forced vital capacity (ppFVC) (ΔppFVC); 28 baseline factors as candidate predictors
- Follow-up
- 24 weeks
Methodological detailspost-hoc analysis, double-blind, placebo-controlled, machine learning causal tree algorithm
- Post-hoc analysis
- Double-blind
- Placebo-controlled
- Machine learning causal tree algorithm
Primary result
As reported in the abstract
ΔppFVC by subpopulation (decision tree on serum C-reactive protein (CRP) and KL-6)
Rituximab vs PlaceboDifference, % (95% CI)
CRP ≥0.055 mg/dl; significantly higher
8.01(4.40%–11.62%)
CRP <0.055 mg/dl and KL-6 ≥364 U/ml; comparable
2.47(−1.99% to 6.92%)
CRP <0.055 mg/dl and KL-6 <364 U/ml; significantly lower
−6.85(−10.80% to −2.91%)
Original publication
Predictors of rituximab efficacy in systemic sclerosis-associated interstitial lung disease: machine-learning analysis of the DESIRES trial. Rheumatology (Oxford). Published 24 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →